EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinicopathological characteristics and treatment outcomes of advanced SMARCA4‐deficient thoracic tumors

Anni Wang iD, Yueping Jin, Zhengqi Cao, Li Lu, Ziming Li

Cancer Medicine · 2024

DOI: 10.1002/cam4.6809 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Anni Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: DNA Helicases, Transcription Factors, Thoracic Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lian Yun Gang Shi Hui Lan Public Foundation, National Multi-disciplinary Treatment Project for Major Diseases, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

SMARCA4‐deficient thoracic tumors, characterized by distinct clinicopathological, morphological, immunohistochemical, and genetic features, differ significantly from conventional non‐small‐cell lung carcinomas (NSCLCs). This group encompasses both SMARCA4‐deficient NSCLCs (SMARCA4‐NSCLCs) and SMARCA4‐deficient undifferentiated tumors (SMARCA4‐UTs). The efficacy of PD‐1 inhibitors in treating SMARCA4‐deficient thoracic tumors remains uncertain.

Methods

Medical records of 36 patients diagnosed with stage IIIB, IIIC, or IV SMARCA4‐deficient thoracic tumors were analyzed. We assessed the clinical, pathological, and genetic features of these patients through immunohistochemistry (IHC) and a 68‐gene panel next‐generation sequencing (NGS). We compared the differences between SMARCA4‐NSCLCs and SMARCA4‐UTs, and evaluated the impact of chemotherapy and immunotherapy on patient outcomes.

Results

The majority of patients with SMARCA4‐deficient thoracic tumors were heavy‐smoking males, averaging 64.6 years in age. IHC predominantly showed weak or negative staining for markers such as TTF‐1, CK5/6, p40, synaptophysin, chromogranin A, and CD56, which are often associated with adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors. The most common genetic mutations identified via NGS included TP53, CDKN2A, KRAS, STK11, NF1, and PTEN. No significant overall survival (OS) difference was observed between SMARCA4‐NSCLCs and SMARCA4‐UTs ( p = 0.366). The median OS for patients treated with chemotherapy ( n = 9) was 447 days, while the median OS for patients undergoing PD‐1‐inhibitor‐based therapy ( n = 16) was not reached ( p = 0.105).

Conclusion

SMARCA4‐deficient thoracic tumors exhibit distinct characteristics from conventional NSCLCs, and PD‐1 inhibitors show promise in treating advanced SMARCA4‐deficient thoracic tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA HelicasesTranscription FactorsThoracic NeoplasmsLung NeoplasmsNuclear ProteinsHumansMaleMiddle AgedFemaleAgedTreatment OutcomeCarcinoma, Non-Small-Cell LungBiomarkers, TumorAdultNeoplasm StagingAged, 80 and overHigh-Throughput Nucleotide SequencingRetrospective StudiesMutationImmune Checkpoint InhibitorsImmunohistochemistry

Stichwörter der Autor:innen

SMARCA4immunotherapythoracic tumorsundifferentiated tumor

Substanzen

SMARCA4 protein, humanDNA HelicasesTranscription FactorsNuclear ProteinsBiomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.

ORCID-Profile: Anni Wang

Förderung

  • Lian Yun Gang Shi Hui Lan Public Foundation
  • National Multi-disciplinary Treatment Project for Major Diseases
  • National Natural Science Foundation of China
  • Program of Shanghai Academic Research Leader
  • Shanghai Municipal Health Commission
  • The Innovative Research Team of High-level Local Universities in Shanghai

Zitieren

APA

Wang, A., Jin, Y., Cao, Z., Lu, L., & Li, Z. (2024). Clinicopathological characteristics and treatment outcomes of advanced SMARCA4‐deficient thoracic tumors. Cancer Medicine. https://doi.org/10.1002/cam4.6809

Vancouver

Wang A, Jin Y, Cao Z, Lu L, Li Z. Clinicopathological characteristics and treatment outcomes of advanced SMARCA4‐deficient thoracic tumors. Cancer Medicine. 2024. doi:10.1002/cam4.6809

BibTeX
@article{Wang2024,
  author = {Wang, Anni and Jin, Yueping and Cao, Zhengqi and Lu, Li and Li, Ziming},
  title = {Clinicopathological characteristics and treatment outcomes of advanced SMARCA4‐deficient thoracic tumors},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6809}
}
Kostenlos starten →